Try our Advanced Search for more refined results

April 04, 2013

Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. October 20, 2014

    Full Fed. Circ. Won't Review BMS Hepatitis Drug Patent Ruling

    The full Federal Circuit refused Monday to review a decision invalidating a Bristol-Myers Squibb Co. hepatitis B drug patent as obvious, even though the compound it was based on was later found to be toxic, but several judges argued strongly that the ruling makes it too hard to show a patent is not obvious.

5 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!